Indication
ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the
prevention of acute and delayed nausea and vomiting associated with initial and
repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting
associated with initial and repeat courses of highly emetogenic chemotherapy.
Important Safety Information:
- ALOXI® is contraindicated in patients known to have hypersensitivity
to the drug of any of its components
- Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting
include headache (9%) and constipation (5%)
For more information about ALOXI® please see full Prescribing Information.
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement
may vary significantly by payor, plan, patient, and setting of care. Actual coverage
and reimbursement decisions are made by individual payors following the receipt
of claims. For additional information, customers should consult with their payors
for all relevant coding, reimbursement, and coverage requirements. It is the sole
responsibility of the provider to select the proper code and ensure the accuracy
of all claims used in seeking reimbursement. All services must be medically appropriate
and properly supported in the patient medical record.
This information is intended for use by our healthcare professionals in the United
States only. Eisai Inc. recognizes the Internet is a global communications medium;
however, laws, regulatory requirements and medical practices for pharmaceutical
products vary from country to country. The Prescribing Information included here
is not appropriate for use outside the United States. This site contains information
about products that may have different product labeling in different countries.
ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland,
used under license.
Distributed and marketed by Eisai Inc. CORP74AR6 ©2012
Eisai Inc. All rights reserved.
This site was last modified on : December 19, 2011 at 5:45pm ET
